Literature DB >> 26864695

Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.

Heng Fan1, Zhen-Yi Shao2, Yuan-Yuan Xiao3, Zhi-Hui Xie2, Wen Chen2, Hua Xie2, Guo-You Qin1, Nai-Qing Zhao4.   

Abstract

PURPOSE: The Glasgow Prognostic Score (GPS) and modified Glasgow Prognostic Score (mGPS) are shown to be reliable prognostic indexes in patients with operable and inoperable non-small cell lung cancer (NSCLC). Considering the difference between the two indexes lies in whether hypoalbuminemia without an elevated C-reactive protein (CRP) is associated with worse survival, this study aims to evaluate the prognostic performance of hypoalbuminemia in patients without an elevated CRP and to compare the prognostic value of GPS and mGPS in patients with operable and inoperable NSCLC.
METHODS: The data of 2988 patients were retrospectively collected from the Shanghai Health Information Network. Univariate and multivariate Cox regression was performed to investigate the prognostic effect of albumin, CRP, GPS and mGPS. Restricted cubic spline was also performed to evaluate the relationship between albumin and hazard ratio. Kaplan-Meier survival curves were estimated and compared using the log-rank test. Additional discriminative ability of GPS and of mGPS was evaluated using the area under the curve and Harrell's concordance index.
RESULTS: Hypoalbuminemia was associated with worse survival in both operable and inoperable patients without an elevated CRP. The Kaplan-Meier survival curve of hypoalbuminemic patients without an elevated CRP was more close to the curve of patients with an elevated CRP and a normal albumin than to the curve of patients with neither of these abnormalities. Multivariate analysis, AUC and C-index all indicated that GPS had a higher prognostic value than mGPS.
CONCLUSIONS: Hypoalbuminemia was associated with worse survival in patients with or without an elevated CRP. GPS was superior to mGPS in predicting survival in operable and inoperable NSCLC patients.

Entities:  

Keywords:  Albumin; C-reactive protein; Glasgow Prognostic Score; Modified Glasgow Prognostic Score; Non-small cell lung cancer; Survival

Mesh:

Substances:

Year:  2016        PMID: 26864695     DOI: 10.1007/s00432-015-2113-0

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  40 in total

Review 1.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

2.  Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer.

Authors:  Donald C McMillan; Joseph E M Crozier; Khalid Canna; Wilson J Angerson; Colin S McArdle
Journal:  Int J Colorectal Dis       Date:  2007-01-24       Impact factor: 2.571

3.  Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer.

Authors:  Masaki Tomita; Takanori Ayabe; Eiichi Chosa; Kunihide Nakamura
Journal:  Anticancer Res       Date:  2014-06       Impact factor: 2.480

4.  Preresection serum C-reactive protein measurement and survival among patients with resectable non-small cell lung cancer.

Authors:  Marco Alifano; Pierre E Falcoz; Valérie Seegers; Nicolas Roche; Olivier Schussler; Mohamad Younes; Filippo Antonacci; Patricia Forgez; Agnes Dechartres; Gilbert Massard; Diane Damotte; Jean-François Régnard
Journal:  J Thorac Cardiovasc Surg       Date:  2011-08-26       Impact factor: 5.209

5.  Is hypoalbuminemia an independent prognostic factor in patients with gastric cancer?

Authors:  Andrew B C Crumley; Robert C Stuart; Margaret McKernan; Donald C McMillan
Journal:  World J Surg       Date:  2010-10       Impact factor: 3.352

6.  Inflammation-based scoring is a useful prognostic predictor of pulmonary resection for elderly patients with clinical stage I non-small-cell lung cancer.

Authors:  Takuro Miyazaki; Naoya Yamasaki; Tomoshi Tsuchiya; Keitaro Matsumoto; Masaki Kunizaki; Daisuke Taniguchi; Takeshi Nagayasu
Journal:  Eur J Cardiothorac Surg       Date:  2014-12-29       Impact factor: 4.191

7.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

8.  Should patient-rated performance status affect treatment decisions in advanced lung cancer?

Authors:  Esther Dajczman; Goulnar Kasymjanova; Harvey Kreisman; Nelda Swinton; Carmela Pepe; David Small
Journal:  J Thorac Oncol       Date:  2008-10       Impact factor: 15.609

9.  The relationship between the insulin-like growth factor-1 axis, weight loss, an inflammation-based score and survival in patients with inoperable non-small cell lung cancer.

Authors:  Claire L Meek; A Michael Wallace; Lynn M Forrest; Donald C McMillan
Journal:  Clin Nutr       Date:  2009-09-11       Impact factor: 7.324

10.  The relationship between Glasgow Prognostic Score and serum tumor markers in patients with advanced non-small cell lung cancer.

Authors:  Ai-Gui Jiang; Hong-Lin Chen; Hui-Yu Lu
Journal:  BMC Cancer       Date:  2015-05-10       Impact factor: 4.430

View more
  34 in total

1.  Modified glasgow prognostic score in patients with small-cell lung cancer.

Authors:  Koichi Kurishima; Hiroko Watanabe; Hiroichi Ishikawa; Hiroaki Satoh; Nobuyuki Hizawa
Journal:  Mol Clin Oncol       Date:  2017-05-12

2.  Prognostic Impact of Indicators of Systemic Inflammation and the Nutritional Status of Patients with Resected Carcinoma of the Ampulla of Vater: A Single-Center Retrospective Study.

Authors:  Yuji Shimizu; Ryo Ashida; Teiichi Sugiura; Yukiyasu Okamura; Takaaki Ito; Yusuke Yamamoto; Katsuhisa Ohgi; Shimpei Otsuka; Akifumi Notsu; Katsuhiko Uesaka
Journal:  World J Surg       Date:  2021-10-18       Impact factor: 3.352

3.  Pretreatment BAN Score Based on Body-mass-index, Albumin and Neutrophil-lymphocyte Ratio Could Predict Long-term Survival for Patients with Operable Esophageal Squamous Cell Carcinoma.

Authors:  Fei Zhang; Li-Jia Bu; Rong Wang; Jie Da; Jin-Xia Ding; Wan-Ren Peng
Journal:  J Cancer       Date:  2022-06-13       Impact factor: 4.478

4.  Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis.

Authors:  Feng Qi; Yunqiu Xu; Yuxiao Zheng; Xiao Li; Yang Gao
Journal:  Ann Transl Med       Date:  2019-10

5.  Clinical utility of the modified Glasgow prognostic score in lung cancer: A meta-analysis.

Authors:  Jing Jin; Kejia Hu; Yongzhao Zhou; Weimin Li
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

6.  The peripheral monocyte count is associated with the density of tumor-associated macrophages in the tumor microenvironment of colorectal cancer: a retrospective study.

Authors:  Masatsune Shibutani; Kiyoshi Maeda; Hisashi Nagahara; Tatsunari Fukuoka; Shigetomi Nakao; Shinji Matsutani; Kosei Hirakawa; Masaichi Ohira
Journal:  BMC Cancer       Date:  2017-06-05       Impact factor: 4.430

7.  A new prognostic score based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer.

Authors:  Lizhen Zhu; Xiaofen Li; Yanwei Shen; Ying Cao; Xuefeng Fang; Jiaqi Chen; Ying Yuan
Journal:  Onco Targets Ther       Date:  2016-08-08       Impact factor: 4.147

8.  The preoperative sensitive-modified Glasgow prognostic score is superior to the modified Glasgow prognostic score in predicting long-term survival for esophageal squamous cell carcinoma.

Authors:  Rui Tian; Fei Zhang; Peng Sun; Jing Wu; Hong Yan; Ai-Ran Wu; Min Zhang; Yu-Lu Jiang; Yan-Hong Lu; Qiu-Yan Xu; Xiao-Hong Zhan; Rong-Xin Zhang; Li-Ting Qian; Jie He
Journal:  Oncotarget       Date:  2016-10-11

9.  The role of the systemic inflammatory response in predicting outcomes in patients with operable cancer: Systematic review and meta-analysis.

Authors:  Ross D Dolan; Jason Lim; Stephen T McSorley; Paul G Horgan; Donald C McMillan
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

10.  Lymphocyte to Monocyte Ratio and Modified Glasgow Prognostic Score Predict Prognosis of Lung Adenocarcinoma Without Driver Mutation.

Authors:  Seigo Minami; Shouichi Ihara; Sung-Ho Kim; Suguru Yamamoto; Kiyoshi Komuta
Journal:  World J Oncol       Date:  2018-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.